The start of the sprint is to focus on the research and development of the project. Shiyans bio-pharmaceutical health industry has a strong momentum of development

Hubei Wudang Animal Pharmaceutical Co., Ltd. is one of the important veterinary drug manufacturers in central China. Not long ago, the new veterinary drug baicalin injection developed by the company won the Hubei Provincial Science and Technology Progress Award. Once the product is on the market, it will sell well. Chen Guoming, chairman of Hubei Wudang Animal Pharmaceutical Co., Ltd., said that the product has obtained international patents. At present, the company's orders for baicalin injection are more than 10 million yuan, with a daily output of 200000 tubes.

Behind the sufficient orders is the result of the company's increasing research and development. With the help of the counterpart cooperation of the South-to-North Water Diversion Project, the company has established a cooperative relationship with the revised pharmaceutical industry, and has successively introduced new varieties of advanced veterinary drugs to accelerate the transformation of scientific and technological achievements.

Chen Guoming said that the company has developed six new drugs of three categories, one of which is baicalin injection. It took six years to obtain the new drug certificate, and then reported the document number. This year, it is expected to achieve 200 million yuan, with a tax of 5 million yuan.

At present, the company has 13 dosage forms, including injection, oral preparation, traditional Chinese medicine extraction workshop and granule workshop, and 14 production lines, with an annual design capacity of more than 500 million yuan. This year, the company has invested in 10 new production lines, with the output value reaching 2 billion yuan after completion.